News Merck agrees $3.9 billion takeover of SpringWorks Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.
News NEJM responds to claims of bias from Justice Department The New England Journal of Medicine (NEJM) has hit back at assertions of bias in its editorial policies from Republican activist Edward Martin Jr.
News Akeso PD-1 inhibitor cleared as Keytruda challenger advances Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.
News Granite Bio makes $100m debut, and other bio financings Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.
News Irish study promises to revolutionise childhood cancer care A five-year genomics study that aims to transform the care of children with cancer and improve treatment success has launched in Ireland.
News Can Bioxodes end the dearth of haemorrhagic stroke drugs? There is currently no approved treatment for intracerebral haemorrhagic stroke, but Belgian start-up Bioxodes hopes to change that.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
